Incyte announced that the US Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of its ruxolitinib …
By Genia Turanova There’s nothing like cash to show how successful a company has been. When a fledgling enterprise first turns cash-flow positive …
This morning, Incyte (NASDAQ:INCY) announced that the company’s ECHO-301 study comparing epacadostat in combination with pembrolizumab with pembrolizumab alone in melanoma failed to …
Raymond James’ Reni Benjamin may scale back his expectations on INCY, but still bets on 24% in return potential for shares.
Eli Lilly and Company and Incyte Corporation (NASDAQ:INCY) announced that five abstracts featuring data from three clinical studies and separate pharmacology studies for …
Incyte Corporation (NASDAQ:INCY) announced that 23 abstracts detailing studies from its clinical development pipeline, including those conducted by Incyte, Novartis and independent investigators, …
Agenus, Inc (NASDAQ: AGEN) announced a global alliance with Incyte Corp. (NASDAQ: INCY) to develop cancer therapies.
Cowen analyst Eric Schmidt maintained an Outperform rating on Incyte (NASDAQ:INCY), following the news that the company’s Jakafi gained FDA approval for the treatment …
In a research report issued yesterday, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Incyte (NASDAQ:INCY) and slightly raised his price …